We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely [Yahoo! Finance]
Sagimet Biosciences Inc. - Series A (SGMT)
Company Research
Source: Yahoo! Finance
after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com? Given this risk, we thought we'd take a look at whether Sagimet Biosciences NASDAQ:SGMT ) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When Sagimet Biosciences last reported its September 2025 balance sheet in November 2025, it had zero debt and cash worth US$117m. Looking at the last year, the company burnt
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. - Series A news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market [Seeking Alpha]Seeking Alpha
- Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom CombinationGlobeNewswire
- Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination ProgramGlobeNewswire
SGMT
Earnings
- 11/13/25 - Beat
SGMT
Sec Filings
- 12/18/25 - Form SCHEDULE
- 12/18/25 - Form 8-K
- 12/17/25 - Form 8-K
- SGMT's page on the SEC website